

Cover Story
A demonstration project in which the Centers for Medicare& Medicaid Services hopes to investigate the impact of reimbursement based on Average Sales Prices of drugs is running into strong opposition, as a large number of cancer groups submitted public comments urging the agency to abandon the endeavor.
In Brief


Drugs & Targets
Trending Stories
- House passes three-year extension of ACA subsidies with bipartisan support
- Nancy Goodman: “Sen. Sanders says he cares about kids with cancer. I’m just asking him to show us.”
- Elisa Rodriguez named first chief diversity and equity officer for faculty at Roswell Park
- Gregory Curt, Clinician and Drug Developer, Dies at 64
- A planned randomized trial will ask an intriguing question: Do COVID vaccines potentiate checkpoint inhibitors?
- Klausner: CRUK Grand Challenge—more than just another grant











